90874-85-4

Basic information

• Product Name: 2-Naphthalenol, 1-amino-1,2,3,4-tetrahydro-
• Synonyms: 2-Naphthalenol, 1-amino-1,2,3,4-tetrahydro-
• CAS NO: 90874-85-4
• Molecular Formula: C₁₀H₁₃NO
• Molecular Weight: 163.22
• Mol File: 90874-85-4.mol
• Article Data: 14

Chemical Properties

• Melting Point: 148 °C
• Boiling Point: 310.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.159±0.06 g/cm3(Predicted)
• PKA: 14.67±0.40(Predicted)
• CAS DataBase Reference: 2-Naphthalenol, 1-amino-1,2,3,4-tetrahydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Naphthalenol, 1-amino-1,2,3,4-tetrahydro-(90874-85-4)
• EPA Substance Registry System: 2-Naphthalenol, 1-amino-1,2,3,4-tetrahydro-(90874-85-4)

Safety Data

• Hazardous Substances Data: 90874-85-4(Hazardous Substances Data)

Usage

General Description

2-Naphthalenol, 1-amino-1,2,3,4-tetrahydro- is a chemical compound with the molecular formula C10H11NO. It is a white to light yellow solid with a strong, sweet, floral odor. 2-Naphthalenol, 1-amino-1,2,3,4-tetrahydro- is used in the production of chemicals and pharmaceuticals, and it may also be used as an intermediate in organic synthesis. It is important to handle this chemical with caution, as it may cause irritation to the skin, eyes, and respiratory tract. Additionally, prolonged or repeated exposure to this compound may have harmful effects on human health.

Upstream product

• 39834-40-7 trans-2-bromo-1,2,3,4-tetrahydronaphthalen-1-ol 
• 1195628-70-6 1-bromo-1,2,3,4-tetrahydronaphthalen-2-ol 
• 530-91-6 1,2,3,4-tetrahydronaphthalen-2 ol 
• 103028-83-7 1-amino-1,2,3,4-tetrahydro-[2]naphthol; hydrochloride 
• 64245-04-1 2-bromo-1-hydroxy-1,2,3,4-tetrahydronaphthalene 
• 2018-87-3 1,2-dibromo-1,2,3,4-tetrahydro-naphthalene 
• 447-53-0 1,2-Dihydronaphthalene 
• 2461-34-9 1,2-epoxy-3,4-dihydronaphthalene 
• 2461-34-9 1a,2,3,7b-tetrahydronaphtho[1,2-b]oxirene 
• 2018-87-3 (+/-)-trans-1,2-dibromo-1,2,3,4-tetrahydronaphthalene 
• 14211-53-1 cis-1,2-dihydroxy-1,2,3,4-tetrahydronaphthalene 
• 7480-36-6 (+/-)-trans-1-amino-2-hydroxy-1,2,3,4-tetrahydronaphthalene 
• 915131-33-8 (+/-)-3,4-dihydro-2-hydroxy-1H-naphthalen-1-one oxime 
• 64559-97-3 2-hydroxy-1-tetralone 

Downstream Products

• 86800-08-0 cis-N-Benzyl-α-amino-β-tetralol 
• 7480-36-6 (+/-)-cis-1-amino-2-hydroxy-1,2,3,4-tetrahydronaphthalene 
• 745072-29-1 2-phenyl-3a,8,9,9a-tetrahydronaphtho[1,2-d]oxazole 
• 209983-03-9 1-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)-amino-1,2,3,4-tetrahydro-2-naphthol 
• 109470-12-4 trans-1-Benzoylamino-2-hydroxy-tetralin 
• 86800-08-0 trans-N-Benzyl-α-amino-β-tetralol 
• 141034-17-5 trans-2-imino-3-acetyl thiazolidine 
• 141034-15-3 trans-2-iminothiazolidine 
• 141034-13-1 trans-N-(2-hydroxy-1,2,3,4-tetrahydronaphthalene-1-yl) thiourea 

Relevant articles and documents

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

Asymmetric synthesis of chiral 1,3-diaminopropanols: Bisoxazolidine- catalyzed C-C bond formation with α-keto amides

Three high-yielding steps lead to the formation of chiral 1,3-diaminopropanols from aliphatic and aromatic α-keto amides. In this approach, a nitroaldol reaction, which is catalyzed by Cu(SO2CF 3)2 and the bisoxazolidine ligand L1, is followed by two mild reduction reactions (see scheme). Laborious protection and deprotection steps can be avoided by using this method.